BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gimeno-Ballester V, Simón MÁ, Trigo C, Mar J, San Miguel R. Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence. Expert Rev Gastroenterol Hepatol 2016;10:1289-303. [PMID: 27626505 DOI: 10.1080/17474124.2016.1236682] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Bruno G, Saracino A, Fabrizio C, Scudeller L, Milano E, Dell'Acqua R, Ladisa N, Fasano M, Minniti S, Buccoliero G, Tartaglia A, Giammario A, Milella M, Angarano G. Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study. Int J Antimicrob Agents 2017;49:296-301. [PMID: 28163136 DOI: 10.1016/j.ijantimicag.2016.11.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
2 Medeiros T, Salviato CM, do Rosário NF, Saraiva GDN, Esberard EBC, Almeida JR, Xavier AR, da Silva AA. Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience. Int J Clin Pharm 2017;39:1304-11. [PMID: 29079938 DOI: 10.1007/s11096-017-0552-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
3 Montasser MF, Zaky S, Salaheldin M, Johar D, Abushouk AI, El-Raey F, Al-Husseini M, Mohammed EG. Fib-4 Predicts Early Hematological Adverse Events Induced by Interferon-Based Triple Therapy in Chronic Hepatitis C Virus Patients. J Interferon Cytokine Res 2019;39:85-94. [PMID: 30657408 DOI: 10.1089/jir.2018.0131] [Reference Citation Analysis]